Publication: 283

A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254
      QxMD      Google Scholar   
Citation:
Leuk Lymphoma vol 52 (4) 587-596
Year:
2011
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
Lymphoma
Sec. Committees:
   
Pharmas:
 
Grants:
U10 CA047577, U10 CA032291, CA04457, CA11789, CA47577, CA32291, CA41287, U10 CA035279, CA03927, U10 CA031946, U10 CA033601, CA59518, CA60138, CA26806, U10 CA059518, CA35279, CA12046, U10 CA077440, CA77440, U10 CA041287, U10 CA047559, CA04326, CA21060, CA47559, CA47642, CA37135, U10 CA047642, CA31983, U10 CA003927, CA07968  
Corr. Author:
 
Authors:
                           
Networks:
 
Study
CALGB-9254
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords:
Lymphoma, anti-B4-blocked ricin, autologous transplant, adjuvant therapy